Acquired Company

Alumis completed its merger with ACELYRIN, Inc. on May 21, 2025, with ACELYRIN stockholders receiving 0.4814 shares of Alumis common stock for each share owned.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California. Show more

Location: 280 East Grand Avenue, South San Francisco, CA, 94080, United States | Website: https://www.alumis.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

2.757B

52 Wk Range

$2.76 - $22.98

Previous Close

$21.09

Open

$20.85

Volume

4,658,515

Day Range

$20.20 - $23.00

Enterprise Value

2.417B

Cash

377.7M

Avg Qtr Burn

-93.1M

Insider Ownership

0.66%

Institutional Own.

64.89%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ESK-001 Details Moderate-to-severe plaque psoriasis	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ESK-001 Details Systemic lupus erythematosus	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
A-005 Details Multiple sclerosis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lonigutamab (IGF-1R Antibody) Details Thyroid Eye Disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.